News
Orzeyful (oveporexton) is now available in the U.S. for adults with narcolepsy type 1
WSCN welcomes an important development for the narcolepsy community. On November 12, 2026, Takeda announced that Orzeyful TM (oveporexton), first-of-its-kind treatment for adults with narcolepsy type 1 (NT1), is now available by prescription in the United States.
For people living with NT1, symptoms can affect life across all 24 hours, from difficulty staying awake during the day to disrupted sleep at night. Cataplexy, a sudden and temporary loss of muscle tone, can add another challenge to daily life. Managing these symptoms can shape how people plan work, school, and everyday activities.
A new approach to treatment
Most existing treatments focus on managing symptoms. Orzeyful is the first FDA-approved treatment for NT1 that directly targets the loss of orexin signaling. It works by activating receptors in the brain to help restore signaling affected by the loss of orexin, a chemical that helps regulate wakefulness.
In clinical studies, adults who took Orzeyful were able to stay awake longer on a daytime wakefulness test, reported less daytime sleepiness, and had fewer episodes of cataplexy per week than adults who took a placebo.
At WSCN, we recognize this as an exciting breakthrough and a meaningful new treatment option for people living with NT1. It is an important step forward in our understanding of central disorders of hypersomnolence and how our brains regulate our sleep-wake cycles each day.
What comes next
Orzeyful is currently approved in the United States for adults with NT1 and can be accessed via a prescription from a licensed healthcare provider. Anyone interested in treatment should speak with their healthcare provider to see if Orezyful is a good fit, and benefits and side effects to consider.
Other hypersomnolence disorders
Orzeyful is not approved for treatment of narcolepsy type 2 (NT2) or idiopathic hypersomnia (IH). Further research is needed to understand whether orexin-based treatments may help people with these conditions, and other medicines are currently being investigated.
